• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Apyx Medical Corporation (Amendment)

    2/13/24 10:58:58 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care
    Get the next $APYX alert in real time by email
    SC 13G/A 1 d10964219_13g-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 8)*

     

     

    APYX MEDICAL CORPORATION
    (Name of Issuer)

     

     

    Common Stock, $0.001 Par Value
    (Title of Class of Securities)

     

     

    03837C106
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     
     

     

     

    CUSIP No 03837C106    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Archon Capital Management LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Washington  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,452,030  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,452,030  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,452,030  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.96%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      OO, IA  

     

     
     

     

     

     

    CUSIP No 03837C106    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Constantinos Christofilis  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,452,030  
         
    7.

    SOLE DISPOSITIVE POWER

     

     
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,452,030  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,452,030  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.96%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  
         

     

     
     

     

    CUSIP No 03837C106    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Strategos Fund, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,981,300  
         
    7.

    SOLE DISPOSITIVE POWER

     

     
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,981,300  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,981,300  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.72%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      PN  
         

     

     
     

     

     

    CUSIP No 03837C106    

     

           
    Item 1. (a). Name of Issuer:  
           
        APYX MEDICAL CORPORATION  
           
      (b). Address of issuer’s principal executive offices:  
           
       

    5115 Ulmerton Road

    Clearwater, Florida 33760

     
           
           
    Item 2. (a). Name of person filing:  
           
       

    Archon Capital Management LLC

    Constantinos Christofilis

    Strategos Fund, L.P.

     
           
      (b). Address of principal business office, or if none, residence:  
           
       

    Archon Capital Management LLC

    1100 19th Avenue E

    Seattle, Washington 98112

     

    Constantinos Christofilis

    c/o Archon Capital Management LLC

    1100 19th Avenue E

    Seattle, Washington 98112

     

    Strategos Fund, L.P.

    c/o Archon Capital Management LLC

    1100 19th Avenue E

    Seattle, Washington 98112

     
           
      (c). Citizenship:  
           
       

    Archon Capital Management LLC – Washington

    Constantinos Christofilis – United States

    Strategos Fund, L.P. – Delaware

     
           
      (d).   Title of class of securities:  
           
        Common Stock, $0.001 Par Value  
           
      (e). CUSIP No.:  
           
        03837C106  

     

     
     

     

     

    Item 3.

    If this Statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:

     

     

      (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [_] A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) [_] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.
     
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)   Amount beneficially owned:
         
       

    Archon Capital Management LLC: 3,452,030

    Constantinos Christofilis: 3,452,030

    Strategos Fund, L.P.: 1,981,300

         
      (b)   Percent of class:
         
       

    Archon Capital Management LLC: 9.96%

    Constantinos Christofilis: 9.96%

    Strategos Fund, L.P.: 5.72%

         

     

      (c)   Number of shares as to which Archon Capital Management LLC has:
         
        (i) Sole power to vote or to direct the vote 0  
             
        (ii)   Shared power to vote or to direct the vote 3,452,030  
             
        (iii) Sole power to dispose or to direct the disposition of 0  
             
        (iv)   Shared power to dispose or to direct the disposition of 3,452,030  

     

        Number of shares as to which Constantinos Christofilis has:
         
        (i) Sole power to vote or to direct the vote 0  
             
        (ii)   Shared power to vote or to direct the vote 3,452,030  
             
        (iii) Sole power to dispose or to direct the disposition of 0  
             
        (iv)   Shared power to dispose or to direct the disposition of 3,452,030  
               
        Number of shares as to which Strategos Fund, L.P. has:
         
        (i) Sole power to vote or to direct the vote 0  
             
        (ii)   Shared power to vote or to direct the vote 1,981,300  
             
        (iii) Sole power to dispose or to direct the disposition of 0  
             
        (iv)   Shared power to dispose or to direct the disposition of 1,981,300  
               

     

     
     

     

     

     

      Instruction:  For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
       
      N/A
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      All securities reported in this Schedule 13G are owned by advisory clients of Archon Capital Management LLC. Other than Strategos Fund, L.P., none of such clients individually own more than 5% of the class of securities reported herein.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      See Exhibit B attached hereto.
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      February 13, 2024
      (Date)
       
      Archon Capital Management LLC*
       
      By: /s/ Constantinos Christofilis
      Name: Constantinos Christofilis
      Title: Managing Member
     

     

     

      CONSTANTINOS CHRISTOFILIS*
      /s/ Constantinos Christofilis
       
       
     

    STRATEGOS FUND, L.P.*

    By: Archon Capital Management LLC, its General Partner

     

      By: /s/ Constantinos Christofilis
      Name: Constantinos Christofilis
      Title: Managing Member

     

     

     

    *The Reporting Persons disclaim beneficial ownership over the securities reported herein except to the extent of their pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Amendment No. 8 to Schedule 13G, dated February 13, 2024, relating to the Common Stock, $0.001 par value, of APYX MEDICAL CORPORATION, shall be filed on behalf of the undersigned.

      Archon Capital Management LLC
       
      By: /s/ Constantinos Christofilis
      Name: Constantinos Christofilis
      Title: Managing Member
       
      CONSTANTINOS CHRISTOFILIS
      /s/ Constantinos Christofilis
       
       
     

    STRATEGOS FUND, L.P.

    By: Archon Capital Management LLC, its General Partner

       
      By: /s/ Constantinos Christofilis
      Name: Constantinos Christofilis
      Title: Managing Member

     

     

     

     

     

     
     

    Exhibit B

     

     

    Archon Capital Management LLC is the relevant entity for which Constantinos Christofilis may be considered a control person.

     

     

     

     

     

     

     

    Get the next $APYX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APYX

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    7/14/2023$8.00Overweight
    Stephens
    5/20/2022$12.00Buy
    Lake Street
    8/13/2021$12.00 → $14.00Market Outperform
    JMP Securities
    More analyst ratings

    $APYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

      4/A - Apyx Medical Corp (0000719135) (Issuer)

      3/3/25 4:05:12 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Roman Shawn David

      4 - Apyx Medical Corp (0000719135) (Issuer)

      1/17/25 4:07:08 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Baylor-Henry Minnie

      4 - Apyx Medical Corp (0000719135) (Issuer)

      1/17/25 4:07:05 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Apyx Medical Corporation

      10-Q - Apyx Medical Corp (0000719135) (Filer)

      5/8/25 12:27:23 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Apyx Medical Corp (0000719135) (Filer)

      5/8/25 6:58:22 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Apyx Medical Corp (0000719135) (Filer)

      4/29/25 8:12:02 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

      4/A - Apyx Medical Corp (0000719135) (Issuer)

      3/3/25 4:05:12 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Hill Matthew C bought $6,030 worth of shares (5,336 units at $1.13), increasing direct ownership by 213% to 7,836 units (SEC Form 4)

      4 - Apyx Medical Corp (0000719135) (Issuer)

      8/13/24 6:56:00 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Hill Matthew C bought $5,475 worth of shares (2,500 units at $2.19) (SEC Form 4)

      4 - Apyx Medical Corp (0000719135) (Issuer)

      12/14/23 9:00:19 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Apyx Medical Corporation

      SC 13G - Apyx Medical Corp (0000719135) (Subject)

      10/31/24 5:44:01 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apyx Medical Corporation

      SC 13G/A - Apyx Medical Corp (0000719135) (Subject)

      10/15/24 9:18:53 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Apyx Medical Corporation (Amendment)

      SC 13D/A - Apyx Medical Corp (0000719135) (Subject)

      5/9/24 7:45:22 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $APYX
    Leadership Updates

    Live Leadership Updates

    See more

    $APYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apyx Medical Corporation Reports First Quarter 2025 Financial Results

      Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March

      5/8/25 7:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures

      Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform marketed and sold as Renuvion®, today announced the publication of two peer-reviewed clinical studies evaluating the use of Renuvion during body contouring procedures that also included lipoabdominopla

      4/29/25 8:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Partic

      4/24/25 8:45:51 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

      NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

      3/1/22 4:05:00 PM ET
      $APYX
      $LNTH
      $PRTK
      $SCPH
      Medical/Dental Instruments
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Pharmaceutical Preparations
    • BTIG Research initiated coverage on Apyx Medical

      BTIG Research initiated coverage of Apyx Medical with a rating of Neutral

      10/17/24 7:28:31 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Stephens initiated coverage on Apyx Medical with a new price target

      Stephens initiated coverage of Apyx Medical with a rating of Overweight and set a new price target of $8.00

      7/14/23 7:29:43 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Apyx Medical with a new price target

      Lake Street initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $12.00

      5/20/22 8:54:50 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Financials

    Live finance-specific insights

    See more
    • Apyx Medical Corporation Reports First Quarter 2025 Financial Results

      Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March

      5/8/25 7:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Partic

      4/24/25 8:45:51 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

      CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth quarter and fiscal year 2024, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international call

      2/27/25 8:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care